KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$235000.0.

  • Aquestive Therapeutics' Cash from Investing Activities fell 19375.0% to -$235000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$492000.0, marking a year-over-year decrease of 20750.0%. This contributed to the annual value of -$159000.0 for FY2024, which is 8402.01% up from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Cash from Investing Activities is -$235000.0, which was down 19375.0% from -$107000.0 recorded in Q2 2025.
  • Aquestive Therapeutics' Cash from Investing Activities' 5-year high stood at -$2000.0 during Q1 2023, with a 5-year trough of -$1.7 million in Q3 2022.
  • Over the past 5 years, Aquestive Therapeutics' median Cash from Investing Activities value was -$104000.0 (recorded in 2022), while the average stood at -$266736.8.
  • As far as peak fluctuations go, Aquestive Therapeutics' Cash from Investing Activities tumbled by 196867.47% in 2022, and later soared by 9807.69% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Cash from Investing Activities (Quarter) stood at -$533000.0 in 2021, then surged by 95.12% to -$26000.0 in 2022, then skyrocketed by 38.46% to -$16000.0 in 2023, then grew by 6.25% to -$15000.0 in 2024, then crashed by 1466.67% to -$235000.0 in 2025.
  • Its Cash from Investing Activities was -$235000.0 in Q3 2025, compared to -$107000.0 in Q2 2025 and -$135000.0 in Q1 2025.